Iontophoresis Drug Delivery to the Macula of Lutein for Age Related Macular Degeneration
Authors:
- Maria Letizia SalvetatMaria Letizia Salvetat
- Francesco PellegriniFrancesco Pellegrini
- Marco ZeppieriMarco Zeppieri
- Matteo CapobiancoMatteo Capobianco
- Alessandro AvitabileAlessandro Avitabile
- Ludovica CannizaroLudovica Cannizaro
- Giuseppe GaglianoGiuseppe Gagliano
- Francesco CappellaniFrancesco Cappellani
- Caterina GaglianoCaterina Gagliano
Open Access
Abstract
Background: Age-related macular degeneration (AMD) represents a leading cause of irreversible vision loss worldwide, driven by intricate interactions among oxidative stress, low-degree chronic inflammation, and macular pigment depletion in aging retinas. Lutein, a component of the macular pigment, has attracted significant attention in AMD management for its antioxidant and blue-light filtering properties. Its oral supplementation, however, although showing potential in slowing AMD progression, requires daily intake and results in variable macular absorption. Trans-scleral iontophoresis (TSI) is a non-invasive technique using low-intensity electric currents to deliver charged molecules into biological tissues and represents an innovative method to deliver lutein into the retina. Methods: The present narrative review synthesizes and discusses the results of lutein supplementation in AMD patients; the ocular iontophoresis basal principles, efficacy, safety and limitations in treating different ophthalmic pathologies; and the evolving clinical evidence supporting lutein TSI in the AMD management. Results: Ex-vivo studies have shown that lutein TSI may provide efficient, localized, rapid, and sustained retinal supplementation of macular pigment, overcoming oral intake limitations. Recent preliminary clinical studies have demonstrated that this technique is well-tolerated and effective in enhancing macular pigment optical density and improving some visual functions in AMD patients. Conclusions: Ex-vivo and pilot clinical studies highlight the capacity of TSI to deliver lutein inside the retina, overcoming physiological barriers that may limit the efficacy of lutein oral administration. The demonstration of the efficacy of the procedure in preserving/improving visual functions and delaying disease progression in AMD patients requires further long-term randomized controlled clinical studies.Keywords
This publication has 172 references indexed in Scilit:
- Age-Related Macular DegenerationJAMA, 2024
- Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular PigmentJAMA Ophthalmology, 2017
- Antioxidant vitamin and mineral supplements for preventing age-related macular degenerationCochrane Database of Systematic Reviews, 2017
- Crystalline Maculopathy Associated With High-Dose Lutein SupplementationJAMA Ophthalmology, 2016
- Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-upJAMA Ophthalmology, 2015
- Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular DegenerationJAMA, 2013
- Reducing the Genetic Risk of Age-Related Macular Degeneration With Dietary Antioxidants, Zinc, and ω-3 Fatty AcidsArchives of Ophthalmology (1950), 2011
- Associations Between Intermediate Age-Related Macular Degeneration and Lutein and Zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS)Archives of Ophthalmology (1950), 2006
- A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision LossArchives of Ophthalmology (1950), 2001
- A Fresh Look at IontophoresisArchives of Ophthalmology (1950), 1984